Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DB2114930: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD
Brief Summary: This is a multicenter, randomized, double-blind, double-dummy, parallel group study. The purpose of this study is to compare the efficacy and safety of umeclidinium/vilanterol (UMEC/VI) and fluticasone propionate/salmeterol (FSC) in subjects with COPD. Subjects who meet the eligibility criteria at Screening will complete a 7 to 14 day Run-in period. At the end of the run-in period, approximately 710 eligible subjects will be equally randomized (to complete at least 568 evaluable subjects) to one of the 2 treatment groups for 12 weeks: 1. UMEC/VI 62.5/25 micrograms (mcg) administered as one inhalation once-daily in the morning via the Novel dry powder inhaler (NDPI) + placebo administered as one inhalation each morning and evening via single multidose powdered inhaler (ACCUHALER/DISKUS) or 2. FSC 250/50 mcg administered as one inhalation each morning and evening via ACCUHALER/DISKUS + placebo administered once-daily in the morning via NDPI. A safety Follow-up assessment will be conducted approximately 7 days after the end of the study treatment (Early Withdrawal, if applicable). The total duration of subject participation will be approximately 15 weeks.


Options:
A: Arm Label: Indacaterol first; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Tiotropium | Arm Label: Tiotropium first; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Tiotropium | Intervention Type: DRUG; Name: Indacaterol; Assigned to Arm(s): Indacaterol first, Tiotropium first | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Indacaterol first, Tiotropium first
B: Arm Label: Olodaterol (BI 1744) Low; Type: EXPERIMENTAL; Interventions: Drug: Olodaterol (BI 1744) | Arm Label: Olodaterol (BI 1744) High; Type: EXPERIMENTAL; Interventions: Drug: Olodaterol (BI 1744) | Arm Label: Formoterol 12mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Olodaterol (BI 1744); Assigned to Arm(s): Olodaterol (BI 1744) Low | Intervention Type: DRUG; Name: Olodaterol (BI 1744); Assigned to Arm(s): Olodaterol (BI 1744) High | Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): Formoterol 12mcg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Umeclidinium/vilanterol Arm; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium/vilanterol, Drug: Placebo | Arm Label: Fluticasone propionate/salmeterol Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/salmeterol, Drug: Placebo | Intervention Type: DRUG; Name: Umeclidinium/vilanterol; Assigned to Arm(s): Umeclidinium/vilanterol Arm | Intervention Type: DRUG; Name: Fluticasone propionate/salmeterol; Assigned to Arm(s): Fluticasone propionate/salmeterol Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fluticasone propionate/salmeterol Arm, Umeclidinium/vilanterol Arm
D: Intervention Type: DRUG; Name: Tiotropium plus Salmeterol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluticasone/Salmeterol; Assigned to Arm(s): N/A

Answer: C